361 results on '"Shami, Paul J."'
Search Results
2. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML
3. Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
4. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia
5. Tattoos and Risk of Hematologic Cancer: A Population‐Based Case–Control Study in Utah.
6. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
7. A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker
8. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center
9. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
10. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
11. Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia
12. Acute myeloid leukemia, version 2.2013.
13. Involvement of Multiple Signaling Pathways in Follicular Lymphoma Transformation: p38-Mitogen-Activated Protein Kinase as a Target for Therapy
14. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
15. Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy
16. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need
17. Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms
18. Development of a Comprehensive Program for Evaluation of Hereditary Predisposition to Hematologic Malignancies
19. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI
20. Effect of a Pluronic® P123 Formulation on the Nitric Oxide-Generating Drug JS-K
21. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs
22. Treatment of acute lymphoblastic leukemia in adults
23. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
24. Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells
25. Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
26. Disease Characteristics of AML Patients with Germline DDX41 Variants
27. Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS
28. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C)
29. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia
30. Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells
31. Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
32. A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
33. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study
34. Additional file 1 of A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker
35. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
36. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O2-(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles
37. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy
38. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells
39. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
40. Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
41. Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia
42. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo
43. Pancreatic Carcinoma Surveillance in Patients With Familial Melanoma
44. Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases
45. Identification and characterization of a novel gene that is upregulated in leukaemia cells by nitric oxide
46. Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
47. A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).
48. Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study
49. Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine
50. Evidence of increased angiogenesis in patients with acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.